Prana Biotechnology Limited (Prana) is an Australia-based development stage medical biotechnology Company. The Company is engaged in commercializing research into Alzheimer's disease, Huntington disease and other major age-related degenerative disorders. The Company's lead drug candidate, PBT2 is being developed for the treatment of Alzheimer’s and Huntington's diseases. Prana Biotechnology is developing therapies to treat neurodegenerative disease. Prana Biotechnology also has advanced a drug candidate for Parkinson’s disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. The Company's activities are predominantly within Australia and cover research into Alzheimer's disease and other major age-related degenerative disorders.